Pediatric rheumatology

Critical care outcomes of hemophagocytic lymphohistiocytosis in children: a single centre retrospective observational study

Pediatr Rheumatol Online JPublished Retrospective observational study

Authors' conclusion

In this cohort, mortality among children admitted to the PICU with HLH was high, particularly among those with primary or onco-hematological forms. Conversely, patients with MAS experienced more relapses but no mortality was observed in this sample. Early presence of splenomegaly, low platelet count, elevated ferritin levels, and PIM2 score at PICU admission appear to be indicators of poor prognosis.

Study context

Population
Children with hemophagocytic lymphohistiocytosis (HLH) admitted to the pediatric intensive care unit (PICU), 2006–2019
Participants
48 children
Exposure
Non-survivors vs survivors; pHLH vs sHLH vs macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis (sJIA)
  • pHLHn = 5
  • sHLHn = 37
  • MASn = 6
Outcome
PICU mortality
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Overall PICU mortality
33.3%

Observational data: associations, not effects.

Further findings

Prognostic factors, non-survivors vs survivors

Pediatric Index of Mortality (PIM2) higher among non-survivors
Splenomegaly and leukopenia at PICU admission more common in non-survivors
Multiple organ failure and acute renal failure during PICU stay more common in non-survivors
Platelet counts significantly lower in patients who died, only at T2 (highest ferritin)
Ferritin consistently elevated in non-survivors throughout PICU stay

Original publication

Critical care outcomes of hemophagocytic lymphohistiocytosis in children: a single centre retrospective observational study. Pediatr Rheumatol Online J. Published 6 July 2026. doi:10.1186/s12969-026-01241-4

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.